Clonazepam monotherapy for epilepsy in childhood
Related Experiment Videos
Insights
Clonazepam effectively reduced seizures in children with epilepsy, with 77% experiencing seizure disappearance. This epilepsy treatment showed minimal side effects, making it a promising option for pediatric patients.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy is a common neurological disorder in children.
- Various antiepileptic drugs are used, but efficacy and side effect profiles vary.
- Clonazepam has shown potential in treating different seizure types.
Purpose of the Study:
- To evaluate the efficacy and safety of clonazepam in children with epilepsy.
- To determine the effectiveness of clonazepam in different seizure types (generalized vs. partial).
- To assess the impact of clonazepam on electroencephalogram (EEG) abnormalities.
Main Methods:
- A study involving sixty pediatric patients (1 month to 14 years) with epilepsy (excluding infantile spasms).
- Treatment with clonazepam was administered.
- Seizure frequency and EEG abnormalities were monitored before and after treatment.
- Dosage and side effects were recorded.
Main Results:
- Seventy-seven percent of patients experienced complete seizure disappearance.
- Fifty percent showed normalization of EEG with seizure cessation.
- Higher efficacy was observed in partial seizures (89%) compared to generalized seizures (71%).
- EEG improvement was noted in 76% of diffuse and 67% of focal paroxysms.
- Low incidence of side effects (5%), primarily drowsiness and ataxia.
Conclusions:
- Clonazepam is an effective treatment for various epilepsy types in children.
- It demonstrates significant efficacy in seizure control and EEG normalization.
- The drug is well-tolerated with a low side effect profile in the pediatric population.
Abstract:
Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam. Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively. Seizures disappeared in 71% of the patients with generalized seizures and 89% of partial seizures. Improvement of abnormal EEG was noticed in 76% of diffuse paroxysms and in 67% of focal paroxysms. In excellent cases, mean effective dosages were 0.086 +/- 0.021 mg/kg/day in infants and 0.057 +/- 0.022 mg/kg/day in schoolchildren, this difference was statistically significant (p less than 0.005). The incidence of side effects such as drowsiness and ataxia was only 5%.